Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers
Kowa Pharmaceuticals America and Eli Lilly (NYSE: LLY) released Subday results from a pharmacokinetic study exploring potential drug interaction between the cholesterol medication pitavastatin (LIVALO) 4 mg and the protease inhibitor combination darunavir/ritonavir (Prezista/Norvir) 800mg/100mg in healthy volunteers.1 The study, presented at the 19th International AIDS Conference in Washington, DC, found that when co-administered, the blood levels for LIVALO and each of the PIs were not significantly affected.1 In February 2012, the PK data darunavir/ritonavir were added to the LIVALO label.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.